BioOutsource Launches Flagship Reverse Signaling Apoptosis Bioassay
Presents webinar on improving speed to market for Biosimilars
GLASGOW, Scotland and BOSTON, Mass –24 March , 2014 – BioOutsource Ltd. (“BioOutsource”), a global leader in biologics contract testing and BioSimilar characterisation for the biopharmaceutical industry, today announced the launch of the flagship Reverse Signaling Apoptosis Bioassay, adding to the extensive range of characterisation services offered by the company. The assay is a critical method, required by the regulators for licensure of Humira and Remicade BioSimilars.
The Reverse Signaling Apoptosis bioassay replicates a critical component of TNF-Alpha biology whereby membrane bound TNF-Alpha acts as a receptor, mediating a negative feedback system following binding by the TNF2 receptor. This results in cytokine suppression and the induction of apoptosis in TNF-Alpha producing cells, thereby dampening the elevated immune response.
BioOutsource CSO, Dr Daniel Galbraith commented; “We are delighted to be the first to bring the Reverse Signalling Apoptosis Assay to market. It completes our extensive range of characterisation testing capabilities and ensures BioOutsource now support the full biological characterisation of Humira and Remicade BioSimilars.”
In addition, BioOutsource also announced that Dr. Galbraith will shortly present a webinar on How Biological Characterisation is improving speed to market for BioSimilars.
Dr. Galbraith commented “The webinar will present how the biological characterisation of BioSimilar Monoclonal Anitbodies plays a critical role in the development pathway for Biosimilars. I am looking forward to presenting our extensive experience in this area and engaging with thought leaders in the industry in the Q&A section”. The webinar is being hosted in partnership with Business Review Webinars on 27th March 2014 at 3pm GMT.
BioOutsource has also announced that it will shortly be exhibiting at CHI’s Biotherapeutics Analytical Summit in Baltimore, USA on 24-28th March 2014, followed by Informa’s, BioProcessing International European Summit in Prague, Czech Republic on 2-3rd April 2014.
For more information on our upcoming conferences and events please follow this link.
MassBio Membership gives you:
Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members.
Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.
MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.
Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.
Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.
Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!
Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.